FDA Approves Kisunla for Alzheimer's Treatment, Marking Significant Progress
On Tuesday, the Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. This approval marks a major milestone in the fight
FDA approves a new Alzheimer's drug. What to know about Eli Lilly's Kisunla
The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.
Lilly drug to slow Alzheimer’s disease gains FDA approval
Lilly’s drug that can slow Alzheimer’s disease has received the approval of the U.S. Food and Drug Administration; the Indianapolis-based pharmaceutical giant announced Tuesday. FDA advisers voted unanimously in June that donanemab’s ability to slow the disease outweighs its risks,
FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $3.5 billion and $2.0 billion respectively by 2030.
FDA approves donanemab, now Kisunla, to treat early Alzheimer’s
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.
FDA approves a second Alzheimer’s drug that can modestly slow disease
U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease. It's only the second drug that's been convincingly shown to slow the memory-destroying condition.
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD),
FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
The FDA today approved Eli Lilly’s Kisunla™ (donanemab-azbt), a once-monthly treatment for adults with early Alzheimer's disease.
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Eli Lilly received FDA approval for a drug to help treat Alzheimer's on Tuesday after studies showed it could help slow the progress of the disease. The treatment, which is called donanemab and will be sold under the brand name Kisunla, is a monthly IV infusion.
Alzheimer’s drug from Eli Lilly wins backing of FDA committee
An advisory committee to the Food and Drug Administration on Monday endorsed an Alzheimer’s drug made by Eli Lilly, setting the stage for the agency to approve another medication that has shown it can slow the progression of the disease.
U.S. Regulator Approves Eli Lilly's Alzheimer's Drug
The U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Eli Lilly's (LLY) Alzheimer's drug called "Donanemab." Eli Lilly's medication for early-stage Alzheimer's disease is one of only a few treatment options available for the brain disease and is expected to provide the company with blockbuster sales.
KSL3h
New Alzheimer's drug wins approval after FDA delay
The U.S. Food and Drug Administration on Tuesday approved another drug that slows cognitive and functional decline in people ...
health.wusf.usf.edu1h
A new Alzheimer's treatment clinic is coming to Sarasota
The clinic will provide two medications that can slow the progression of the disease in early stages: Leqembi and Kisunla.
Monthly Prescribing Reference5d
Kisunla Approved for Early Symptomatic Alzheimer Disease
The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.
Zacks.com on MSN3d
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly LLY won a long-awaited FDA approval for its Alzheimer's disease (AD) drug, donanemab, to be sold under the brand ...